Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Gene therapy provides a promising approach in treating cancers with high efficacy and selectivity and few adverse effects. Currently, the development of functional vectors with safety and effectiveness is the intense focus for improving the delivery of nucleic acid drugs for gene therapy. For this purpose, stimuli-responsive nanocarriers displayed strong potential in improving the overall efficiencies of gene therapy and reducing adverse effects via effective protection, prolonged blood circulation, specific tumor accumulation, and controlled release profile of nucleic acid drugs. Besides, synergistic therapy could be achieved when combined with other therapeutic regimens. This review summarizes recent advances in various stimuli-responsive nanocarriers for gene delivery. Particularly, the nanocarriers responding to endogenous stimuli including pH, reactive oxygen species, glutathione, and enzyme, etc., and exogenous stimuli including light, thermo, ultrasound, magnetic field, etc., are introduced. Finally, the future challenges and prospects of stimuli-responsive gene delivery nanocarriers toward potential clinical translation are well discussed. The major objective of this review is to present the biomedical potential of stimuli-responsive gene delivery nanocarriers for cancer therapy and provide guidance for developing novel nanoplatforms that are clinically applicable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 1×
“The major nucleic acid drugs for the treatment of cancers include small interfering RNA (siRNA) [18–20], antisense oligonucleotides [21, 22], microRNA [23, 24], messenger RNA [25–29], short hairpin RNA, and gene editing systems (e.g., CRISPR/Cas9 system) [30–32].”
BackgroundNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184 · cited 1×
“Currently, gene therapy as an emerging revolutionary treatment technology can specifically regulate and amend the expression of any aberrant gene in cancer cells in theory [10, 11].”
BackgroundLee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511
Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
Naeem, M., Majeed, S., Hoque, M. Z., & Ahmad, I. (2020) · Cells · doi:10.3390/cells9071608 · Cited by 457
Non-viral gene delivery systems
Davis, M. E. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00294-x · Cited by 419 · cited 1×
“Tumorigen-esis and progression involve the abnormal expression and mutation of a variety of genes, which are often participated in cell proliferation, differentiation, aging, death, and other processes [8, 9].”
Background
Cited by
Hu, D., Li, Y., Li, R., Wang, M., Zhou, K., He, C., Wei, Q., & Qian, Z. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.10.015 · Cited by 153
Biomacromolecular hydrogel scaffolds from microfluidics for cancer therapy: A review
Hao, S., Shi, L., Li, J., Shi, J., Kuang, G., Liang, G., & Gao, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136738 · Cited by 7
Self-citation
Metadata
- Authors
- Zhang, Q., Kuang, G., Li, W., Wang, J., Ren, H., & Zhao, Y.
- Venue
- Nano-Micro Letters
- Published
- 2023-02-08
- Volume
- 15
- Issue
- 1
- Pages
- 44-44
- ISSN
- 2150-5551 (ISSN-L)
- 2311-6706
- OpenAlex
- W4319457762
- Cited by
- 178
- References
- 20
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy. https://app.cochat.ai/papers/10.1007/s40820-023-01018-4
- The paper
- Zhang, Q., Kuang, G., Li, W., Wang, J., Ren, H., & Zhao, Y. (2023). Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy. Nano-Micro Letters. https://doi.org/10.1007/s40820-023-01018-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.